Advertisement

HIV-Associated Multicentric Castleman’s Disease

  • Christian HoffmannEmail author
  • Eric Oksenhendler
  • Laurence Gérard
Chapter

Abstract

Multicentric Castleman’s disease (MCD) is a rare but potentially fatal lymphoproliferative disorder that shows a close association with human herpesvirus-8 (HHV-8) infection. Interleukin-6 dysregulation is thought to be fundamental to its pathogenesis. MCD is characterized by recurrent flares with fever, lymphadenopathy, splenomegaly, and heterogeneous systemic manifestations, associated with cytopenia, raised inflammatory markers, and high HHV-8 viral load in the blood. During the recent years, the widespread use of combination antiretroviral therapy and the introduction of rituximab have dramatically improved the treatment of HIV-MCD.

Keywords

Primary Effusion Lymphoma Mantle Zone Polyclonal Hypergammaglobulinemia Intravenous Etoposide Lytic Viral Replication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Alzahrani M, Hull MC, Sherlock C, Griswold D, Leger CS, Leitch HA. Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome. Leuk Lymphoma. 2015;56:1246–51.CrossRefPubMedGoogle Scholar
  2. 2.
    Bérezné A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood. 2004;103:4368–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Boshoff C, Begent RH, Oliver RT, et al. Secondary tumours following etoposide containing therapy for germ cell cancer. Ann Oncol. 1995;6:35–40.PubMedGoogle Scholar
  4. 4.
    Bower M, Newsom-Davis T, Naresh K, et al. Clinical features and outcome in HIV-associated multicentric Castleman’s disease. J Clin Oncol. 2011;29:2481–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Int Med. 2007;147:836–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Bower M. How I, treat HIV-associated multicentric Castleman disease. Blood. 2010;116:4415–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Retroviral-mediated transfer of interleukin-6 into hematopoietic cells of mice results in a syndrome resembling Castleman’s disease. Curr Top Microbiol Immunol. 1990;166:37–41.PubMedGoogle Scholar
  8. 8.
    Castleman B, Towne VW. Case records of the Massachusetts General Hospital: case no. 40231. N Eng J Med. 1954;250:1001–5.CrossRefGoogle Scholar
  9. 9.
    Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling lymphoma. Cancer. 1956;9:822–30.CrossRefPubMedGoogle Scholar
  10. 10.
    Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood. 2001;97:2130–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Du MQ, Bacon CM, Isaacson PG. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and lymphoproliferative disorders. J Clin Pathol. 2007;60:1350–7.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood. 2000;95:1406–12.PubMedGoogle Scholar
  13. 13.
    Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman’s disease: ANRS 117 CastlemaB trial. J Clin Oncol. 2007;25:3350–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Gérard L, Michot JM, Burcheri S, et al. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. Blood. 2012;119:2228–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8 – specific CD8+ T cells. Blood. 2008;111:1387–95.CrossRefPubMedGoogle Scholar
  16. 16.
    Hoffmann C, Schmid H, Müller M, et al. Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. Blood. 2011;118:3499–503.CrossRefPubMedGoogle Scholar
  17. 17.
    Jung CP, Emmerich B, Goebel FD, Bogner JR. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol. 2004;75:176–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi’s sarcoma and primary effusion lymphoma. Curr Opin Oncol. 2005;17:447–55.CrossRefPubMedGoogle Scholar
  19. 19.
    Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman’s disease. Eur J Haematol. 2006;76:269–71.CrossRefPubMedGoogle Scholar
  20. 20.
    Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman’s disease by thalidomide. Am J Hematol. 2003;73:48–53.CrossRefPubMedGoogle Scholar
  21. 21.
    Li H, Wang H, Nicholas J. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling. J Virol. 2001;75:3325–34.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Marcelin A-G, Motol J, Guihot A, et al. Relationship between the quantity of Kaposi sarcoma-associated herpesvirus (KSHV) in peripheral blood and effusion fluid samples and KSHV-associated disease. J Infect Dis. 2007;196:1163–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996;274:1739–44.CrossRefPubMedGoogle Scholar
  24. 24.
    Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman’s disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10:25–35.PubMedGoogle Scholar
  25. 25.
    Nagao A, Nakazawa S, Hanabusa H. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases. J Hematol Oncol. 2014;7:10.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Naresh KN, Rice AJ, Bower M. Lymph nodes involved by multicentric Castleman disease among HIV-positive individuals are often involved by Kaposi sarcoma. Am J Surg Pathol. 2008;32:1006–12.CrossRefPubMedGoogle Scholar
  27. 27.
    Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627–32.CrossRefPubMedGoogle Scholar
  28. 28.
    Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman’s disease. Int J STD AIDS. 2003;14:61–2.CrossRefPubMedGoogle Scholar
  29. 29.
    Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99:2331–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood. 2000;96:2069–73.PubMedGoogle Scholar
  31. 31.
    Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman’s disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61–7.CrossRefPubMedGoogle Scholar
  32. 32.
    Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009;4:16–21.CrossRefPubMedGoogle Scholar
  33. 33.
    Polizzotto MN, Uldrick TS, Wang V, et al. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Blood. 2013;122:4189–98.PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    Polizzotto MN, Uldrick TS, Hu D, Yarchoan R. Clinical manifestations of Kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome. Front Microbiol. 2012;3:73.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman’s disease. Ann Oncol. 2009;20:775–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood. 2007;110:4132–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Scott D, Cabral L, Harrington Jr WJ. Treatment of HIV-associated multicentric Castleman’s disease with oral etoposide. Am J Hematol. 2001;66:148–50.CrossRefPubMedGoogle Scholar
  38. 38.
    Soulier J, Grollet L, Oksenhendler E, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1276–80.PubMedGoogle Scholar
  39. 39.
    Stebbing J, Adams C, Sanitt A, et al. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood. 2011;118:271–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Stone K, Woods E, Szmania SM, et al. Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman disease and is associated with increased soluble interleukin-6 receptor levels. PLoS One. 2013;8:e54610.PubMedCentralCrossRefPubMedGoogle Scholar
  41. 41.
    Talat N, Schulte KM. Castleman’s disease: systematic analysis of 416 patients from the literature. Oncologist. 2011;16:1316–24.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Tedeschi R, Marus A, Bidoli E, Simonelli C, De Paoli P. Human herpesvirus 8 DNA quantification in matched plasma and PBMCs samples of patients with HHV8-related lymphoproliferative diseases. J Clin Virol. 2008;43:255–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Uldrick TS, Polizzotto MN, Aleman K, et al. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. Blood. 2014;124:3544–52.PubMedCentralCrossRefPubMedGoogle Scholar
  44. 44.
    Uldrick TS, Polizzotto MN, Aleman K, et al. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977–86.PubMedCentralCrossRefPubMedGoogle Scholar
  45. 45.
    Uldrick TS, Wang V, O’Mahony D, et al. An interleukin-6-related systemic inflammatory syndrome in patients co-infected with Kaposi sarcoma-associated herpesvirus and HIV but without Multicentric Castleman disease. Clin Infect Dis. 2010;51:350–8.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15:966–74.CrossRefPubMedGoogle Scholar
  47. 47.
    Zietz C, Bogner JR, Goebel FD, Lohrs U. An unusual cluster of cases of Castleman’s disease during HAART for AIDS. N Engl J Med. 1999;340:1923–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Christian Hoffmann
    • 1
    Email author
  • Eric Oksenhendler
    • 2
  • Laurence Gérard
    • 2
  1. 1.Infektionsmedizinisches Centrum Hamburg (ICH)HamburgGermany
  2. 2.Hôpital Saint-Louis, AP-HP, and EA3963, University Paris DiderotParisFrance

Personalised recommendations